Skip to main content
Erschienen in: International Cancer Conference Journal 4/2018

13.08.2018 | Case report

Locally advanced pancreatic cancer successfully treated with high-dose helical tomotherapy

verfasst von: Yukihiro Hama

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Complete surgical resection is the potentially curative treatment for pancreatic cancer, but only fewer than 20% of those individuals will be found to be eligible for surgery. Here we report a 49-year-old man with locally advanced pancreatic cancer successfully treated with high-dose radiotherapy using helical tomotherapy (66 Gy/33 fractions, 2 Gy per day over 6.5 weeks). To our knowledge, this is the first reported case of locally advanced pancreatic cancer curatively treated with helical tomotherapy alone.
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013 CA. Cancer J Clin 63:11–30CrossRef Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013 CA. Cancer J Clin 63:11–30CrossRef
2.
Zurück zum Zitat Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68–72CrossRefPubMed Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68–72CrossRefPubMed
4.
Zurück zum Zitat Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733CrossRefPubMed Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733CrossRefPubMed
5.
Zurück zum Zitat Zschaeck S, Blumke B, Wust P et al (2017) Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One 12:e0186341CrossRefPubMedPubMedCentral Zschaeck S, Blumke B, Wust P et al (2017) Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One 12:e0186341CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat de Geus SWL, Eskander MF, Kasumova GG et al (2017) Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 123:4158–4167CrossRefPubMed de Geus SWL, Eskander MF, Kasumova GG et al (2017) Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 123:4158–4167CrossRefPubMed
8.
Zurück zum Zitat Taylor R, Opfermann K, Jones BD et al (2012) Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. J Med Imaging Radiat Oncol 56:332–337CrossRefPubMed Taylor R, Opfermann K, Jones BD et al (2012) Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. J Med Imaging Radiat Oncol 56:332–337CrossRefPubMed
9.
Zurück zum Zitat Chang JS, Wang ML, Koom WS et al (2012) High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 83:1448–1454CrossRefPubMed Chang JS, Wang ML, Koom WS et al (2012) High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 83:1448–1454CrossRefPubMed
10.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Dunn JA et al (2001) European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768CrossRefPubMedPubMedCentral Neoptolemos JP, Stocken DD, Dunn JA et al (2001) European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024CrossRef Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024CrossRef
Metadaten
Titel
Locally advanced pancreatic cancer successfully treated with high-dose helical tomotherapy
verfasst von
Yukihiro Hama
Publikationsdatum
13.08.2018
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2018
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-018-0340-3

Weitere Artikel der Ausgabe 4/2018

International Cancer Conference Journal 4/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.